Understand the source comparison
Russian Clinical Dosing Protocols vs Western Longevity Experimentation
Khavinson's published protocols used 5–10mg epithalon administered subcutaneously once daily for 10–20 consecutive days, repeated twice annually. The timing aligned with equinox periods (March and September) when photoperiod shifts trigger natural melatonin pr
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Khavinson's published protocols used 5–10mg epithalon administered subcutaneously once daily for 10–20 consecutive days, repeated twice annually. The timing aligned with equinox periods (March and September) when photoperiod shifts trigger natural melatonin production changes. His rationale: epithalon potentiates existing circadian signals rather than replacing them. Administering during stable photoperiods produces weaker effects because there's no endogenous rhythm shift to amplify.
- Western longevity research has tested alternative protocols. Intermittent dosing (once weekly), lower cumulative doses (2–5mg per administration), and longer cycles (30+ days). None have replicated the lifespan extension results seen in Khavinson's rodent trials, which showed 42% lifespan increase in rats receiving biannual 10-day epithalon courses starting at middle age. The discrepancy likely reflects dosing frequency: epithalon's 30-minute plasma half-life means daily administration maintains consistent tissue exposure, while weekly dosing creates saw-tooth concentration curves that may not sustain receptor occupancy.
- Dosing calculation for subcutaneous administration: epithalon is typically reconstituted at 5mg/mL in bacteriostatic water. A 10mg dose requires 2mL injection volume, administered in the abdomen or thigh using a 1mL insulin syringe for two sequential injections. Rotate injection sites daily to prevent localized irritation. Subcutaneous tissue has limited absorption capacity, and repeated administration at the same site causes fibrous nodules that reduce peptide uptake.